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ABSTRACT
This study aimed to evaluate the diagnostic performance of arterial spin labelling 
(ASL) in grading of adult gliomas. Eighteen studies matched the inclusion criteria and 
were included after systematic searches through EMBASE and MEDLINE databases. 
The quality of the included studies was assessed utilizing Quality Assessment of 
Diagnostic Accuracy Studies-2 (QUADAS-2). The quantitative values were extracted 
and a meta-analysis was subsequently based on a random-effect model with forest plot 
and joint sensitivity and specificity modelling. Hierarchical summary receiver operating 
characteristic (HROC) curve analysis was also conducted. The absolute tumour blood 
flow (TBF) values can differentiate high-grade gliomas (HGGs) from low-grade 
gliomas (LGGs) and grade II from grade IV tumours. However, it lacked the capacity 
to differentiate grade II from grade III tumours and grade III from grade IV tumours. 
In contrast, the relative TBF (rTBF) is effective in differentiating HGG from LGG and in 
glioma grading. The maximum rTBF (rTBFmax) demonstrated the best results in glioma 
grading. These results were also reflected in the sensitivity/ specificity analysis in 
which the rTBFmax showed the highest discrimination performance in glioma grading. 
The estimated effect size for the rTBF was approximately similar between HGGs and 
LGGs, and grade II and grade III tumours, (–1.46 (–2.00, –0.91), p- value < 0.001), 
(–1.39 (–1.89, –0.89), p- value < 0.001), respectively; while it exhibited smaller effect 
size between grade III and grade IV (–1.05 (–1.82, –0.27)), p < 0.05). Sensitivity and 
specificity analysis replicate these results as well. This meta-analysis suggests that 
ASL is useful for glioma grading, especially when considering the rTBFmax parameter.
INTRODUCTION
WHO grade staging of gliomas has implications 
for prognosis and choice of therapy and MRI plays 
a leading role in all phases of tumour management, 
including diagnosis, therapy, and follow-up. T1-weighted 
post contrast MRI allows identification regions of blood 
brain barrier (BBB) disruption [1, 2] which are usually 
associated with higher WHO grades but presence of 
contrast enhancement can be misleading as some low-
grade gliomas (LGGs) demonstrate contrast uptake, with 
lack of enhancement being observed in some high-grade 
gliomas (HGGs) [3]. Arterial spin labelling (ASL), which 
uses magnetically labelled blood water as an inherently 
diffusible tracer, is now performed in clinical settings as, 
unlike contrast-enhanced perfusion MRI techniques, it can 
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provide absolute cerebral blood flow (CBF) quantification, 
eliminates the need for contrast agent, and can be repeated 
for therapy monitoring. Additionally, ASL is less sensitive 
to vessels permeability changes, which suggests that 
it provides tumour perfusion information that reflects 
vascular density [4].
Quantitative ASL measurements have introduced 
as output relative (or normalised) tumour blood flow 
(rTBF) and/or absolute tumour blood flow (TBF) values, 
which have been reported as useful in distinguishing 
between HGGs and LGGs [5–7] and in glioma grading 
[8] with some studies reporting nevertheless negative 
results [9–11]. The purpose of this systematic review 
and meta-analysis was to address this ambiguity and 
provide evidence for the diagnostic accuracy of ASL in 
preoperative glioma grading.
MATERIALS AND METHODS
Literature search and selection
This meta-analysis followed the Preferred Reporting 
Items for Systematic reviews and Meta-Analyses (PRISMA) 
guidelines with the research question being ‘What is the 
diagnostic value of arterial spin labelling (ASL) in the 
differentiation of glioma grades in adult patients?’ [12]. The 
search terms were identified according to the Population/
Intervention/Comparator/Outcomes (PICO category) 
recommendations and were linked by Boolean operators 
(‘OR’ within each PICO category; and ‘AND’ between 
PICO categories). The identified search terms were framed 
in concepts. Concept 1 (P): glioma OR neuroglia OR 
glioma; Concept 2 (I): arterial spin OR artery spin; Concept 
3 (O): diagnosis OR grading OR differentiate. Finally, the 
search was conducted without the third concept in order to 
cast a wider net. As a result, steps 1 and 2 were combined 
[(glioma OR neuroglia OR glioma) AND (arterial spin OR 
artery spin)]. The systematic search was performed in June 
2018 through EMBASE ‘(1974 to 8 June 2018)’ and Ovid 
MEDLINE (R) ‘In-process and other non-indexed citations’ 
databases to find relevant articles that met the defined search 
terms; this resulted in the identification of 111 and 48 items 
respectively. A total of 159 items were found, which were 
rendered to 122 after duplicates were removed. We included 
records focusing on pre-treatment glioma grading in adults 
using ASL. Relevant articles were selected according to 
PRISMA (see relevant flow chart in Figure 1). 104 of them 
were excluded as they did not met the research question; for 
example: they applied ASL in animal models [13] use ASL 
in order to asses the treatment [14, 15] or applied in pediatric 
population [16]. Eventually, 18 studies were deemed eligible 
in terms of the selected inclusion criteria.
Eight out of the 18 studies reported the TBF values as 
a mean and standard deviation, whereas three reported the 
cut-off values and the corresponding diagnostic sensitivity 
and specificity rates. The remaining 7 studies provided all 
the aforementioned information. Due to high variability 
in expressing the TBF amongst the studies, we decided 
to rename the studies output as follows: when the region 
of interest (ROI) included the entire tumour outlined on 
conventional images, the absolute or relative to the healthy 
appearing white matter TBF was referred to as TBFmean/
rTBFmean. When the tumour ROI was placed on the 
highest signal in the perfusion map, the TBF is referred as 
maximum TBFmax/rTBFmax. In some studies, both mean 
and maximum TBF/rTBF values were reported.
The considerable variability in the study 
populations, ASL labelling methods, and acquisition 
parameters in addition to the diversity of post-processing 
analyses process among the included studies could 
potentially limit the power of this study evidence thus 
the Quality Assessment of Diagnostic Accuracy Studies-2 
(QUADAS-2) [17] tool was used by 2 independent 
researchers to assess the risk of bias of the included studies 
and their applicability.
Statistical methods
Analyses were performed for a number of tumour 
WHO grading combinations: HGGs vs. LGGs; grade II 
vs. grade III; grade II vs. grade IV; grade III vs. grade 
IV. All outcomes were measured on a continuous scale. 
The mean, standard deviation (SD) and number of 
subjects were extracted from each individual study. For 
studies where the data range was only reported, the SD 
was assumed to be a quarter of the whole range. Studies 
with no reported measure of variability (e.g. SD, inter-
quartile range, range) were excluded from this analysis 
(study 14 and 17 for rTBFmax, still they provided the 
ROC analysis and TBFmax, respectively). Some studies 
reported the same parameter from both the whole sample 
and sub-group (e.g. study 8, Supplementary Table 2); 
whereas some studies reported the same outcome from 
the same sample using either different ASL techniques 
(e.g. study 16, Supplementary Table 2) or different image 
analysis methodology (e.g. study 18, Supplementary 
Table 1). In such instances, the different data sets from the 
same study were treated as being from ‘different’ studies 
to avoid doubling the study weight. The Chi-square test 
for heterogeneity was used to determine if the results 
from different studies varied significantly. Additionally, 
heterogeneity was quantified using the I2 statistic, which 
gives the percentage of the variability in effect estimates 
that is due to heterogeneity. An I2 value of over 50% was 
regarded as indicating substantial heterogeneity.
Subsequently, the results from the different studies 
were pooled. The measurement scales of some outcomes 
varied, and thus the standardised mean difference (SMD) 
between groups was calculated in preference to the raw 
mean difference. A random-effects model was used for all 
meta-analyses, regardless of the degree of heterogeneity 
between studies. The examination of publication bias 
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Figure 1: Preferred Reporting Items of Systematic Reviews and Meta-Analyses-PRISMA flow chart for the study 
selection process.
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was investigated using graphical methods (Funnel plots) 
examining the association between the effect size (SMD) 
and the uncertainty (standard error) in the calculating 
effect size.
The diagnostic performance (sensitivity and 
specificity) of the ASL in differentiating between HGGs 
and LGGs and in glioma grading were also investigated. 
The data analysis used an approach outlined by Li et al. 
[18, 19] that jointly models the two outcomes (sensitivity 
and specificity), due to the known inverse relationship 
between these two measures. The approach taken here was 
to fit a two-level mixed logistic regression model, with 
independent binomial distributions for the true positives 
and true negatives conditional on the sensitivity and 
specificity in each study, and a bivariate normal model 
for the logit transforms of sensitivity and specificity 
between studies. This approach gives pooled estimates 
of sensitivity and specificity, along with corresponding 
confidence intervals (CI) for each. A hierarchical 
summary receiver operating characteristic (HROC) curve 
was also generated. This analysis was performed using 
the “metandi” command in STATA 15 (StataCorp LLC, 
College Station, TX, USA).
RESULTS
Eligible ASL studies
The studies are grouped according to the applied 
ASL acquisition technique - pseudo-continuous-ASL, 
continuous -ASL and pulsed-ASL (PCASL, CASL, PASL, 
respectively) - and summarised on Supplementary Tables 
1–3. The examined gliomas histology, the ASL technical 
parameters, the selected TBF metrics, and any statistical 
significant difference between HGGs and LGGs are also 
presented on Supplementary Tables 1–3.
QUADAS-2 assessment
Five of the included studies expressed low risk 
of bias and concerns regarding applicability following 
the QUADAS-2 assessment. The summary graph of 
QUADAS-2 assessment is demonstrated in Figure 2. 
The risk of bias graph shows the four domains; the flow 
and timing and the reference standard domains possess 
the lowest risk of bias. The index test domain, could 
introduce bias as in the majority of the included studies 
the reviewers were not blinded to the standard reference 
(high) or the authors did not provide this information. In 
the patient selection domain, about 25% of the eligible 
for meta-analysis studies did not use a consecutive or 
random selection (high) while ~ 25% did not explain 
the process of patient selection (unclear). The concerns 
regarding applicability graph involved three domains; the 
reference standard and the index test domains showed low 
concerns as all the studies included ASL as index test and 
histopathological examination as a reference standard. 
However, the patient selection domain expressed ~10% 
(high) as one of the studies included both adult and 
pediatric patients and another one include residual gliomas 
in their analysis.
Differentiation of HGGs from LGGs
With the exception of TBFmean, there was 
considerable heterogeneity among the studies (Table 1). 
The Chi-square test for heterogeneity was statistically 
significant, and additionally the I2 values were high. All 
ASL-derived biomarkers were found to be significantly 
lower in LGGs than in HGGs. The larger effects 
were observed for the rTBF, where the sizes of group 
differences were typically higher than for the TBF. The 
mean differences between LGGs and HGGs for the 
rTBF was approximately 1.5 SDs. The rTBF funnel plots 
typically showed values outside the confidence limit in 
both directions, reflecting the large study heterogeneity. 
However, there was no clear picture that the effect size 
was associated with the standard error of the SMD to 
suggest publication bias (Egger test, P- value = 0.17, 0.72, 
0.24 for rTBF, rTBFmean and rTBFmax, respectively). 
The TBF funnel-plots suggested that the majority of points 
were within the confidence limits, corroborating the lack 
of obviouas publication bias (Egger test, P- value = 0.05, 
0.43, 0.10 for TBF, TBFmean and TBFmax, respectively). 
A graphical illustration of the results is shown in the 
Supplementary Figures 1–6.
Differentiation of grade II from grade III gliomas
A summary of the analysis results is presented on 
Table 1. rTBF values were characterised by relatively 
small degree of heterogeneity between studies and were 
found to significantly vary between the two investigated 
WHO grades, with substantially lower values in grade II 
patients. The mean rTBF value was 1.4 SDs lower in grade 
II than in grade III patients. There were only two studies 
reporting absolute TBF values, and there was a relatively 
large amount of heterogeneity in them (I2:66%). The 
absolute TBF showed a trend for lower in grade II patients 
by an average of 0.9 SDs. Concerning publication bias, 
all points were within the confidence limits and there was 
no clear evidence of asymmetry of the funnel plot (Egger 
test, P- value = 0.46 for rTBF). Graphical illustrations of 
these results are shown in Supplementary Figures 7 and 8.
Differentiation of grade II from grade IV gliomas
The ASL-derived parameters between grade II and 
grade IV patients are summarised on Table 1. The results 
showed significant heterogeneity among the included 
studies with ASL biomarkers showing significantly lower 
values in grade II patients. The larger effect was observed 
for rTBF, which was 2 SDs lower in grade II patients than 
in grade IV gliomas. The effect size for TBF was substantial 
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(1.4 SDs). The funnel-plot for the rTBF was fairly 
symmetrical suggesting no definite evidence of publication 
bias (Egger test, P- value = 0.25 for rTBF). The results are 
illustrated graphically in Supplementary Figures 9 and 10.
Differentiation of grade III from grade IV gliomas
The differences in ASL-derived tumour perfusion 
between grade III and grade IV gliomas are summarised on 
Table 1: Comparison of the differences in ASL-related biomarkers between HGGs and LGGs and 






size Heterogeneity Effect size
Egger test to evaluate 
publication bias
LGG HGG P-value I2 SMD (95% CI) (*) P-value P-value
rTBF 15 237 323 <0.001 86% –1.46 (–2.00, –0.91) <0.001 0.17
rTBF mean 9 142 192 <0.001 86% –1.53 (–2.26, –0.79) <0.001 0.72
rTBF max 6 95 131 <0.001 87% –1.36 (–2.23, –0.49) 0.002 0.24
TBF 11 155 219 0.002 64% –0.82 (–1.20, –0.45) <0.001 0.05
TBF mean 4 51 70 0.50 0% –0.61 (–0.99, –0.23) 0.002 0.43
TBF max 7 104 149 <0.001 76% –0.96 (–1.53, –0.39) 0.001 0.10
II III
rTBF 4 62 48 0.26 25% –1.39 (–1.89, –0.89) <0.001 0.46
TBF 2 43 21 0.09 66% –0.90 (–1.85, 0.04) 0.06 (-)
II IV
rTBF 4 62 61 <0.001 87% –2.07 (–3.38, –0.76) 0.002 0.25
TBF 2 43 32 0.01 84% –1.44 (–2.76, –0.12) 0.03 (-)
III IV
rTBF 6 54 69 0.006 69% –1.05 (–1.82, –0.27) 0.008 0.19
TBF 4 27 40 0.64 0% –0.45 (–0.95, 0.05) 0.08 0.04
(*) SMD calculated as the difference between LGGs ASL-parameters and HGGs ASL-parameters (usually higher than the 
LGG counterparts).
(-) No pooled results due to low number of included studies.
Figure 2: The Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) results for the included studies. 
Oncotarget1594www.oncotarget.com
Table 1 and suggest a significant degree of heterogeneity 
(I2:69%) through the 6 studies that provided rTBF as 
ASL output. The pooled results suggest significantly 
lower rTBF values in grade III patients compared to their 
grade IV counterparts. The SMD between grades was 1 
SD, which is slightly lower than the difference between 
grade II and III gliomas. The results for TBF showed 
little heterogeneity between studies and a trend for lower 
TBF in the grade III patients (p = 0.08). The funnel plot 
appeared fairly asymmetrical for TBF, with obviously 
larger SMD values being found in the smaller studies 
(owing to larger standard errors) and smaller effects in the 
larger patient cohorts (with smaller SE) but not for the 
rTBF (Egger test, P- value = 0.04, 0.19 for TBF and rTBF, 
respectively). For both ASL-derived parameters, there was 
some suggestion of publication bias (see Supplementary 
Figures 11 and 12).
HROC curve analysis of ASL-based histological 
grading
The diagnosic performance of ASL for determining 
the individual glioma grades (Table 2) was characterised 
by high sensitivity (>90%) for diffrentiation between 
grade II and III. The sensitivity was slightly lower for the 
classification between grade III and IV, but still relatively 
high. This is in agreement with the aforementioned 
results as the effect size between grade II and grade 
III gliomas was higher than that between the grade III 
and grade IV tumours. The method specificity for the 
individual tumour grading was below 70%. Both the 
95% confidence and prediction regions indicate wide 
variability of the true sensitivity and specificity. The ASL 
sensitivity, specificity, negative predictive value (NPV) 
and positive predictive value (PPV) for various cut-
off values in glioma grading from the involved studies 
illustrated on Supplementary Table 4. The HROC plots 
are showed on Figure 3.
HROC curve analysis of ASL-based 
differentiation between HGGs and LGGs
The overall results suggested relatively high 
sensitivity and specificity, both approx. 85%, by using 
ASL biomarkers to stratify the gliomas in HGGs and 
LGGs. There was a similar level of sensitivity for each of 
the individual ASL parameters under analysis. Specificity 
was slightly more variable ranging from 79% for rTBF 
mean up to 92% for rTBF max. Both the 95% confidence 
and prediction regions indicate wide variability of the true 
sensitivity and specificity. A summary of the results is 
presented on Table 3. The sensitivity, specificity, negative 
predictive value (NPV) and positive predictive value 
(PPV) of various cut-off ASL values among glioma grades 
from the involved studies are shown in Supplementary 
Table 5 with the HROC plots presented in Figure 4.
DISCUSSION
The results of this meta-analysis indicate that 
the absolute TBF can be used to differentiate HGGs 
from LGGs as well as grade II from grade IV gliomas. 
However, absolute TBF could not discriminate grade II 
from grade III and grade III from grade IV glial tumours. 
In contrast, rTBF was more effective than absolute 
TBF in differentiating HGGs from LGGs and presented 
satisfactory accuracy in glioma grading. In addition, 
rTBFmax parameter demonstrated the best performance in 
glioma grading overall. The same result was observed in 
the sensitivity and specificity analysis where the rTBFmax 
provided the highest sensitivity and specificity values. The 
estimated effect size for rTBF was approximately similar 
between HGGs and LGGs (-1.46 (-2.00, -0.91), p- value < 
0.001), and between grade II and grade III (-1.39 (-1.89, 
-0.89), p- value < 0.001), while it expressed smaller 
effect size between grade III and grade IV (-1.05 (-1.82, 
-0.27)), p < 0.05). The same result was also noticed in 
the sensitivity and specificity analyses. Fudaba et al. also 
reported that rTBFmax provided higher sensitivity and 
specificity than rTBFmean [20].
The systematic literature review and the 
heterogeneity analysis highlighted the variations across 
the included studies, which could be due to inclusion of 
mixed glioma types, the applied ASL approaches and its 
parameters (e.g post-labelling-delays (PLD)), and the 
method of image processing and analysis. Notably, all 
studies that reported the inability of ASL to distinguish 
HGGs from LGGs [9–11] were conducted in mixed 
gliomas patient cohorts. This sounds rational as even low-
grade oligodendrogliomas are associated with elevated 
perfusion and thus introduce diagnostic bias [7, 21]. A 
study that included only oligodendrogliomas found also 
impossible to determine the WHO grade using ASL 
biomarkers [22]. On contrary, a handful of studies in 
astrocytomas demonstrated that ASL can identify HGGs 
from LGGs [23–25] and grade them accordingly with 
remarkable sensitivity and specificifity [8, 20]. In spite 
of that, other studies with mixed glioma types reported 
the efficiency of ASL in differentiating between HGGs 
and LGGs [6, 7] and glioma grading [5]. The 2016 WHO 
classification of brain tumours puts more emphasis on the 
genetic and molecular subtyping of gliomas by stratifying 
them according to the isocitrate-dehydrogenase-(IDH) and 
1p/19q mutation status or co-deletion, respectively [26]. 
The ASL studies reviewed in this meta-analysis lacked 
information about molecular and genetic subtypes of 
gliomas, which is likely to represent a source of variation 
as the IDH-wild gliomas has been reported to have higher 
perfusion values than those with IDH-mutation [9, 27].
The different ASL labelling approaches and 
acquisition parameters across the included studies 
obviously result in quantitative ASL metrics variation. 
The three common ASL labelling methods used in these 
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sample size Sensitivity (95% CI) Specificity (95% CI) AUC (95% CI)
II vs. III 4 52 64 94% (75%, 99%) 61% (48%, 73%) 0.76, (0.72, 0.79)
II vs. IV 3 (*) (*) (*) (*) (*)
III vs IV 9 148 75 86% (75%, 93%) 69% (57%, 79%) 0.75, (0.71, 0.79)
(*) No pooled results due to low number of included studies.
Figure 3: HROC plot of the summary point of the sensitivity and the specificity (square) and its 95% CI (the green 
curve) of rTBF from ASL to differentiate between. (A) grade II and grade III (94%, CI (75%, 99%)) and (61%, CI (48%, 73%)), 
respectively; (B) grade III and grade IV (86%, CI (75%, 93%)) and (69%, CI (57%, 79%)), respectively.
Table 3: Diagnostic performance of the ASL imaging biomarkers in stratifying the tumours 
between HGGs and LGGs
Biomarker Number of studies
Total sample size
Sensitivity (95% CI) Specificity (95% CI) AUC (95% CI)
LGGs HGGs
All 17 206 397 86% (78%, 91%) 84% (76%, 90%) 0.91, (0.89, 0.93)
TBF 1 (*) (*) (*) (*) (*)
rTBF 16 181 370 86% (77%, 91%) 84% (76%, 90%) 0.91, (0.89, 0.94)
rTBF max 5 76 122 85% (69%, 94%) 92% (80%, 97%) 0.95, (0.93, 0.97)
rTBF mean 8 80 188 84% (71%, 92%) 79% (66%, 88%) 0.87, (0.84, 0.90)
(*) No pooled results due to low number of included studies.
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studies were the pulsed-ASL (PASL); the continuous-
ASL (CASL); and the pseudo-continuous-ASL (PCASL). 
PASL is the most widely used technique due to its broad 
availability, the low specific absorption rate (SAR), and 
the robust labelling efficiency [28] across a wide range 
of blood velocity. However, this method suffers from the 
lowest signal-to-noise-ratio (SNR) in comparison to the 
other labelling methods. CASL is subject to higher SAR 
and lower labelling efficiency than PASL. PCASL has 
the advantages of both CASL (high SNR) and PASL (low 
SAR) however, its labelling efficiency is lower than that 
of PASL. Thus, PCASL has been reported to demonstrate 
Figure 4: HROC plot shows the summary point of the sensitivity and the specificity (square) and its 95% CI (the green 
curve). (A) from all of the analysed ASL parameters to differentiate between HGGs and LGGs (86%, CI (78%, 91%)) and (84%, CI (76%, 
90%)), respectively; (B) rTBF to differentiate between HGGs and LGGs (86%, CI (77%, 91%)) and (84%, CI (76%, 90%)), respectively; 
(C) rTBFmean to differentiate between HGGs and LGGs (84%, CI (71%, 92%)) and (79%, CI (66%, 88%), respectively; (D) rTBFmax to 
differentiate between HGGs and LGGs (85%, CI (69%, 94%)) and (92%, CI (80%, 97%)).
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the best reproducibility among all aforementioned ASL 
labelling methods, at least in healthy volunteers [29].
All but two studies with negative results [9, 30] 
that applied PASL in gliomas showed its efficiency in 
differentiating between HGGs and LGGs [7, 20, 23–
25, 31, 32] and in glioma grading [8]. All studies that 
utilised CASL in gliomas [21, 22, 30] were promising in 
differentiation between HGGs and LGGs. Nonetheless, 
recent studies drew conflicting conclusions regarding 
the usefulness of PCASL acquisitions as it helped to 
identify HGGs from LGGs [6] and to perform grading 
[5], whilst a couple of publications didn’t confirm the 
findings [9–11]. This discrepancy could be due to the low 
labelling efficiency of PCASL, which varies between 
scanners and patients. Another important acquisition 
parameter in ASL is the inversion time (TI), also called 
post labelling delay (PLD). Selection of the most suitable 
TI in tumours tends to be challenging as ASL acquisition 
at a single TI reduces the sensitivity to the blood transit 
time but does not eliminate it. This sensitivity can be 
considered by the use of multiple PLDs [33] in CASL/
PCASL or by quantitative-image of perfusion using a 
single-subtraction-(QUIPSS-II) [34]/ QUIPSS-II with 
thin slice TI1 periodic saturation (Q2TIPS) [35] in PASL. 
Generally, the delay time has to be long enough to enable 
all the labelled blood bolus to transfer from the capillary 
bed to the target tissue in the labelling plane, but short 
enough to preserve the signals from T1-decay. Furtner 
et al. identified the most effective TI for determining 
the HGGs from the LGGs astrocytomas at 370 ms [23]. 
Other studies employed variable single delay times 
within a range of 1200–1900 ms, and reported similar 
or lower sensitivity and specificity [6, 8, 20, 24, 30, 31]. 
Unlike using a single TI, the use of multiple TIs makes 
CBF quantification more reliable and less sensitive to 
bolus arrival time. Cebeci et al. used 8 TIs to distinguish 
HGG from LGG [7] and Yang et al. acquired ASL at 16 
TIs in astrocytomas, which not only differentiated HGGs 
from LGGs, but also enabled glioma grading [8].
The reported tumour perfusion was heavily skewed 
by the non-standardised ROI analysis on the calculated 
CBF maps. Normalised TBF values (also known 
as rTBF) have been widely used as they reduce the 
values scatterring within a group by mitigating age and 
hemodynamic variations related risks [25]. Also, patients 
with brain tumours usually present elevated intracranial 
pressure, which in turn reduces the global CBF and the 
accuracy of the estimation of regional TBF. On the other 
hand, several authors argue that the use of rTBF leads to 
variation between observers due to random error caused 
by the internal reference on the normal tissue [36, 37]. 
This could partially explain the high variation in the 
rTBF of malignant tumours. Nevertheless, the relative 
values are considered more reliable than the absolute 
TBF values when distinguishing between HGGs and 
LGGs [7, 25] which has also been confirmed by our 
meta-analysis. Previous ASL tumour studies have used 
various normal brain regions for normalisation, including 
the GM [38] the WM [31], the mean of both [32], or 
the contralateral normal tissue mirrored to tumour [25]. 
Interestingly, the mirror ROI yielded better results than 
GM and WM as an internal standard [39], which is most 
likely due to the approximately similar distance from 
the labelling plane. Nevertheless, the majority of studies 
have used the contralateral normal appearing white 
matter for normalisation purposes [5, 8, 20, 22, 24, 31, 
40]. Furthermore, it is important to note that the image 
employed to delineate the tumour mask may affect the 
reliability and validity of results. A number of studies 
generated tumour mask from the MRI-conventional image 
whilst others selected the ROI through visual inspection 
of the maximum signal intensity visually on the ASL-
subtracted image or the M0 image. Regarding the choice 
of contrast-enhanced T1-weighted images as reference for 
tumour mask, we should bear in mind that the enhanced 
tissue represents blood brain barrier disruption (BBB) 
rather than increased perfusion [41].
In line with our meta-analysis results, TBFmax 
has been reported to be more precise than TBFmean for 
tumour characterisation [42, 43]. This is plausible, as 
HGGs tend to be heterogeneous, and hence the TBFmax 
will be representative of the most anaplastic tumour 
part. In addition, TBFmean estimation is affected by the 
partial volume effect making the TBFmax more suitable 
as a biomarker. Nevertheless, histogram analysis [44, 45] 
that also captures the tumour heterogeneity is probably 
the method with the highest diagnostic accuracy and 
reproducibility.
Several studies have examined ASL feasibility 
and its complementary role in routine brain tumour 
examinations by comparing it with more well-established 
MRI methods; to other MRI-perfusion methods, 
dynamic susceptibility contrast-enhanced (DSC) [7, 
25, 43] and dynamic contrast-enhanced (DCE) [9, 
10] to MRI-diffusion methods (MRI diffusion) [5, 
6, 31] and to MR-spectroscopy (MRS) [20, 22, 32]. 
Currently, dynamic susceptibility contrast (DSC) is 
the clinically most utilised MR perfusion technique 
in brain tumour examinations. However, arterial spin 
labelling (ASL), is useful for those who could not 
tolerate high-rate contrast injection or (relatively) 
contraindicated to the usage of contrast agent (impaired 
renal function, allergies, paediatric population) along 
with raising issues over the permanent gadolinium 
depositions in brain [46]. The studies that involved 
both indexed examinations in glioma grading, focused 
on the use of ASL as an alternative or surrogate of 
DSC [7, 25, 37] e.g. by examining the correlation or 
interchangeability of the estimated perfusion metrics 
from each examination, rather than suggesting which 
method is superior. As a matter of fact, these studies 
demonstrate the non-inferiority of ASL in the specific 
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patient cohorts. Warmuth et al. reported a strong positive 
correlation between the rTBF measurement from ASL 
and DSC [25]. Another study measured rTBFmax and 
rTBFmean reporting excellent correlation between ASL 
and DSC [37]. Cebeci et al. used PASL to demonstrate 
moderate but still significant correlation between the 
rTBF values from the ASL and DSC [7]. These studies 
provide preliminary evidence that ASL can be used 
as a non-invasive alternative to DSC addressing the 
shortcoming of non-diffusible tracer (gadolinium) 
in DSC that leaks out of dysfunctional BBB and may 
lead to underestimation of the rTBF measurement [47]. 
In addition, there is scarce evidence on the prognostic 
role of each perfusion techniques [48–53], where rCBV 
measurements seem to provide the best sensitivity and 
specificity to predict tumor recurrence and survival time 
in gliomas patients [54].
Two of the included studies in this meta-analysis 
examined the correlation between ASL and DCE in 
gliomas [9, 10]. Both studies (utilising PASL and 
PCASL) suggested that ASL was not an effective method 
for glioma grading and reported poor to moderate 
correlation between ASL and DCE. This might be 
attributed to a variation in ROI selection and number of 
high-grade gliomas in each study. In order to consider 
ASL as a viable alternative to other MRI perfusion 
methods (DSC and DCE), its reproducibility and inter-
observer variability in patients with brain tumours have 
to be tested. A number of studies have reported good 
inter-observer variability in tumour patients using PASL 
[8, 24] quantitative STAR labeling of arterial regions 
(QUASAR) [42] and PCASL [5, 11]. Hirai et al. reported 
excellent reproducibility in glioma patients using both 
maximum and mean TBF [42].
Regarding the future directions of ASL imaging in 
tumours, Yoo et al. recenty used PCASL to investigate 
the connection between the HGGs perfusion values and 
genetic biomarkers [55] and found the epidermal growth 
factor receptor (EGFR) to be significantly correlated with 
rTBF and absolute TBF. Furthermore, Yamashita et al. 
demonstrated that TBF and rTBF values were significantly 
greater in GBM patients with IDH-wild type status than 
those with IDH-mutation [27] and Brendle et al. reported 
that ASL, unlike DCE, could stratify astrocytomas 
accortding to the IDH-mutation status [9].
There are some limitations in our study. First, 
approximately all the evaluated perfusion metrics founde to 
be heterogenous among the included studies in this meta-
analysis. This is expected, because heterogeneity among 
MRI measurments are unavoidable as they differ from center 
to center and even between platformas in the same center. 
However, this heterogeneity has been taken into account 
in the analysis stage via random effect model utilization. 
Second, the small sample size of the included studies (18 
studies). Still, this reflect the strict methodological standard 
in order to be faithfull to the assigned research question.
CONCLUSIONS
This meta-analysis aimed to shed light into the 
diagnostic performance of ASL in glioma grading and 
demonstrated the suitability of ASL-derived perfusion 
metrics in glioma grading. rTBFmax showed the best 
diagnostic and staging performance. Hence, ASL metrics 
capacity as imaging biomarkers can be routinely useful 
for the characterisation and staging of gliomas at baseline, 
with possible implications for treatment selection and 
surveillance imaging. However, further research with 
larger numbers of patients and well defined tumour 
subtypes, including molecular information, is needed to 
refine any TBF-relate threshold values that allow higher 
diagnostic and prognostic accuracy and are essential for 
the wide dissmination of the technique.
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